SEC Form 4 · accession 0000310158-26-000221
Merck & Co., Inc. · MRK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jennifer Zachary
Officer — EVP, General Counsel
Period of report
Aug 12, 2026
Accepted (ET)
Aug 13, 2026 · 4:11 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000310158
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 12, 2026 | M | 41,494 | $117.89 | A | 112,391 | D | |
| Common Stock | Aug 12, 2026 | M | 13,433 | $84.71 | A | 125,824 | D | |
| Common StockF1 | Aug 12, 2026 | S | 80,315 | $133.4557 | D | 45,509 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $117.89 | Aug 12, 2026 | M | 41,494 | D | May 2, 2024 | May 1, 2033 | Common Stock | 41,494 | 0 | D |
| Stock Option (Right to Buy)F3 | $84.71 | Aug 12, 2026 | M | 13,433 | D | Apr 29, 2026 | Apr 28, 2035 | Common Stock | 13,433 | 0 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.0300 to $133.5000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- F2The options vested and became exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026.
- F3The options vest and become exercisable in equal installments on 4/29/2026, 4/29/2027, and 4/29/2028.